Skip to main content
Holiday Sale — Get 40% off Vantage for yourself or as a gift
Get Started
SubscribeLogin
Published • loading... • Updated

The Nantes Biotech Ose Immunotherapeutics Revises Its Agreement with Abbvie and Redefines Its Priorities

Summary by usinenouvelle.com
Ose Immunotherapeutics has reviewed the conditions of its major partnership with AbbVie, sealed since 2024 and which had earned it 48 million euros. The Nantes biotech sees its role evolve in the development of ABBV-230, the candidate-drug concerned by the agreement, positioned on severe chronic inflammation.
DisclaimerThis story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.Cross Cancel Icon

1 Articles

usinenouvelle.comusinenouvelle.com

The Nantes Biotech Ose Immunotherapeutics Revises Its Agreement with Abbvie and Redefines Its Priorities

Ose Immunotherapeutics has reviewed the conditions of its major partnership with AbbVie, sealed since 2024 and which had earned it 48 million euros. The Nantes biotech sees its role evolve in the development of ABBV-230, the candidate-drug concerned by the agreement, positioned on severe chronic inflammation.

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.

Factuality Info Icon

To view factuality data please Upgrade to Premium

Ownership

Info Icon

To view ownership data please Upgrade to Vantage

usinenouvelle.com broke the news in on Thursday, December 11, 2025.
Too Big Arrow Icon
Sources are mostly out of (0)
Blindspot Title And Logo
Stories disproportionately reported by the Left or the Right

Similar News Topics

AbbVie icon

AbbVie

Nantes icon

Nantes

News
Feed Dots Icon
For You
Search Icon
SearchBlindspot LogoBlindspotLocal